EGFR and non-small cell lung carcinoma: Among NSCLC cases tested by plasma NGS that were negative for EGFR sensitizing mutations, additional actionable findings were made in nine of 42 cases (21.4%), and other genomic findings (any other nonactionable mutations from the 49 gene LiquidHALLMARK® panel) were made in 42.8% (18/42) cases.